Fair Value Measurements (Narrative) (Detail) - USD ($) shares in Thousands, $ in Thousands		1 Months Ended		3 Months Ended		9 Months Ended
		Mar. 21, 2017	Dec. 21, 2016	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Jun. 30, 2017	Nov. 30, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized gain on interest rate swap						$ 1,539
Accrued contingent consideration				$ 752		752		$ 2,952
Impairment charges for goodwill and intangibles	[1]			256,266		$ 256,266
Number of shares to be issued	[1]					5,122
Aggregate principal amount of notes									$ 143,750
Theoretical borrowing rate used to calculate fair value of debt									6.50%
Fair value of the notes				126,600		$ 126,600
Fair value of future issuance of shares				90,400		90,400
Human Health Segment - Rising Reporting Unit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Goodwill impairment charge				235,110		235,110
Impairment charges for goodwill and intangibles				256,266		256,266
Human Health Segment - Rising Pharma
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Intangible asset and recognized an impairment charge				5,745		5,745
Customer relationships | Human Health Segment - Acetris Health
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Intangible asset and recognized an impairment charge				15,411		15,411
Foreign currency contract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount				62,350		62,350
Unrealized gains (losses) on hedging activities				(34)	$ 353	227	$ (230)
Cash flow hedging | December 21, 2021 | Interest rate swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Additional interest cost rate of derivative		2.005%
Derivative, notional amount		$ 100,000
Derivative, expiration date		Dec. 21, 2021
Notional balance of derivative				87,500		87,500
France Company
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued contingent consideration				89		89		145
Citron and Lucid
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued contingent consideration				$ 663		$ 663		$ 2,807
Number of shares to be issued			5,122	5,122		5,122

[1] (as restated)